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SUMMARY 
Most individuals with arterial hypertension or congestive heart failure are insulin-resistant and at a higher risk of 
developing type 2 diabetes (T2DM). The inhibition of the renin-angiotensin system (RAS), using an angiotensin 
converting enzyme inhibitor (ACEI) or a selective angiotensin receptor AT1 blocker (ARB), may exert 
favourable metabolic effects capable of preventing T2DM in high risk individuals. We performed a meta-
analysis of randomised clinical trials (RCTs) assessing the effects of RAS inhibition on the incidence of new 
cases of T2DM in patients with arterial hypertension or congestive heart failure. Ten RCTs with cardiovascular 
prognosis as primary endpoints analysed the incidence of T2DM as secondary endpoints or as post-hoc analysis 
after a mean follow-up of 1 to 6 years: five with an ACEI and five with an ARB, compared with a placebo (n = 
4) or a reference drug (beta-blocker or diuretic: n = 5; amlodipine: n = 2). Eight RCTs concerned hypertensive 
patients: STOP Hypertension-2 (lisinopril or enalapril vs beta-blocker or diuretic), CAPPP (captopril vs thiazide 
or beta-blocker), HOPE (ramipril vs placebo), ALLHAT (lisinopril vs chlorthalidone and lisinopril vs 
amlodipine), LIFE (losartan vs atenolol), SCOPE (candesartan vs placebo), ALPINE (candesartan vs placebo) 
and VALUE (valsartan vs amlodipine). Two RCTs concerned patients with congestive heart failure: SOLVD 
(enalapril vs placebo) and CHARM-overall programme (candesartan vs placebo). Overall, 2 675 new cases of 
T2DM (7.40%) were observed in the group of 36167 patients receiving a treatment with ACEI or ARA as 
compared with 3 842 events (9.63%) in the group of 39 902 control patients. A mean weighed relative risk 
reduction of new T2DM of 22% (95% CI: 18, 26; p < 0.00001) was observed after RAS inhibition. The 
beneficial effect was similar with ACEIs and with ARBs as well as in patients with hypertension and in those 
with heart failure, and was also present whatever the comparator (placebo or beta-blockers/diuretics or 
amlodipine). The number needed-to-treat to avoid one new case of T2DM averaged 45 patients over 4-5 years. 
In conclusion, RAS inhibition consistently and significantly reduces the incidence of T2DM in individuals with 
arterial hypertension or with congestive heart failure. Considering the pandemic of T2DM, such pharmacological 
approach deserves further attention among the strategies aiming at preventing T2DM. 
Key-words: ACE inhibitors – Angiotensin – AT1 receptor blockers – Hypertension – Congestive heart failure – 
Meta-analysis – Type 2 diabetes mellitus. 
 
 
L'inhibition du système rénine-angiotensine prévient le diabète de type 2. 
Partie 1. Méta-analyse des essais cliniques randomisés 
RESUME 
La plupart des personnes avec hypertension essentielle ou décompensation cardiaque congestive sont 
insulinorésistantes et davantage sujets à développer un diabète de type 2 (DT2). Le blocage du système rénine-
angiotensine (RAS), en utilisant un inhibiteur de l'enzyme de conversion de l'angiotensine (IEC) ou un 
antagoniste sélectif des récepteurs AT1 de l'angiotensine II (ARA), peut exercer des effets métaboliques 
favorables capables de prévenir la survenue d'un DT2 chez des sujets à risque. Nous avons réalisé une méta-
analyse des essais cliniques randomisés ayant analysé les effets d'une inhibition du RAS sur l'incidence de 
nouveaux cas de DT2 chez des sujets hypertendus ou décompensés cardiaques. Dix études, ayant comme objectif 
principal le pronostic cardio-vasculaire, ont analysé l'incidence de DT2, soit comme critère d'évaluation 
secondaire, soit lors d'une analyse post-hoc, après un suivi moyen de 1 à 6 années : cinq avec un IEC et cinq 
avec un ARA, par comparaison à un placebo (n = 4) ou un médicament de référence (bêta-bioquant ou 
diurétique: n = 5 ; amlodipine: n = 2). Huit essais ont concerné des sujets hypertendus: STOP Hypertension-2 
(lisinopril ou énalapril vs bêta-bloquant ou diurétique), CAPPP (captopril vs thiazide ou bêta-bloquant), HOPE 
(ramipril vs placebo), ALLHAT (lisinopril vs chlorthalidone et lisinopril vs amlodipine), LIFE (losartan vs 
aténolol), SCOPE (candésartan vs placebo), ALPINE (candésartan vs placebo) et VALUE (valsartan vs 
amlodipine). Deux essais ont concerné des patients avec insuffisance cardiaque: SOLVD (énalapril vs placebo) 
et CHARM (candesartan vs placebo). Au total, 2 675 nouveaux cas de diabète (7,40 %) ont été observés dans le 
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groupe des 36167 patients bénéficiant d'un IEC ou d'un ARA par comparaison à 3 842 événements (9,63 %) 
dans le groupe des 39 902 patients témoins. La méta-analyse montre une réduction relative du risque, avec une 
moyenne pondérée de 22 % (95 % IC : 18,26 ; p < 0,00001), pource qui concerne la survenue d'un DT2 après 
inhibition du RAS. L'effet bénéfique est comparable avec un IEC ou un ARA, se retrouve chez les patients avec 
hypertension artérielle ou insuffisance cardiaque et est observé quel que soit le comparateur (placebo ou bêta-
bloquant/diurétique ou amlodipine). Le nombre de sujets à traiter pour éviter un nouveau cas de DT2 est de 45 
patients sur une période de 4-5 années. En conclusion, l'inhibition du système rénine-angiotensine réduit, de 
façon consistante et significative, l'incidence de DT2 chez les personnes avec hypertension artérielle ou 
décompensation cardiaque congestive. Compte tenu de la pandémie de DT2, cette intervention pharmacologique 
mérite une attention particulière parmi les différentes stratégies visant à prévenir cette maladie. 
Mots-clés : Angiotensine – Diabète de type 2 – Hypertension – Inhibiteur de l'enzyme de conversion –
Insuffisance cardiaque – Méta-analyse – Sartan. 
 
INTRODUCTION 
Arterial hypertension is intimately associated with type 2 diabetes mellitus (T2DM) [1]. Both elevated arterial 
pressure and impaired glucose tolerance (IGT) are key-components of the metabolic syndrome ("syndrome X" or 
insulin resistance syndrome), a leading cause of cardiovascular morbidity and mortality [2, 3]. Patients with 
essential hypertension have been shown to have a higher risk of developing T2DM than non-hypertensive 
individuals in several large prospective studies on various populations [4, 5]. Antihypertensive agents may exert 
negative, neutral or even positive metabolic effects that may diversely affect the risk of developing T2DM [6]. 
The renin-angiotensin system (RAS) is a coordinated hormonal cascade in the control of cardiovascular, renal, 
and adrenal function. It governs fluid and electrolyte balance and blood pressure regulation, but may also exert 
various, although still poorly understood, cellular effects [7]. RAS inhibition plays a key-role in cardiovascular 
pharmacology. Pharmacological agents include angiotensin-converting enzyme inhibitors (ACEIs), that block 
the conversion of pro-hormone angiotensin I to active hormone angiotensin II, and selective angiotensin II 
receptor-1 blockers (ARBs). Both compounds are now widely used as first-line antihypertensive agents in 
patients with diabetes mellitus, essentially because of their renal protection effect [8]. 
Recent data showed that RAS inhibition may result in a significant reduction in the incidence of T2DM in 
patients with arterial hypertension [6, 9] or with congestive heart failure (CHE) [9]. We performed a meta-
analysis of randomised clinical trials (RCTs) that assessed the incidence of new cases of T2DM as secondary 
endpoints or as post-hoc analysis in addition to the effects of RAS inhibition on cardiovascular prognosis, used 
as primary endpoint, in patients with essential hypertension or CHF [10]. 
MATERIAL AND METHODS 
To identify relevant studies, we searched MEDLINE, EMBASE, Science citation index (Web of Science and ISI 
Proceedings) from January 1990 to June 2004. We also searched the reference lists of identified studies assessing 
the effects of RAS inhibition on the cardiovascular prognosis. Searching was limited to English-language papers. 
Studies were considered eligible for inclusion in the metaanalysis only if they compared either an ACEI or an 
ARB with a reference drug (either placebo or active drug) within a RCT Studies should also concerned non-
diabetic individuals with arterial hypertension or CHF. Furthermore, accurate data should be provided in the 
selected papers regarding the total number of patients included in the trial, the mean duration of follow up, the 
number of non-diabetic individuals at baseline, the criteria used to define diabetes, the number of new cases of 
T2DM during follow up. 
Details of participant characteristics (age, gender, body mass index, comorbidity, lost of follow up) and study 
design (primary and secondary objectives, dose titration, coexisting drugs, statistical analysis) were carefully 
recorded. 
Meta-analysis was conducted for new diabetes throughout the follow-up period in patients receiving either an 
ACEI or an ARB and in patients receiving the reference drug. Data in the form of odds ratios (OR) and 95% 
confidence intervals (95% CI) were analysed using the Mantel-Haenszel method, fixed-effect model provided by 
the RevMan Analyses 1.0 application contained in RevMan 4.2 [11]. Heterogeneity was tested by the chi-square 
test in RevMan Analyses 1.0. 
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RESULTS 
A total of ten cardiovascular RCTs assessed as secondary objective or in a post-hoc analysis the potential 
prevention of diabetes by ACEIs (five RCTS) (Tab I) or ARBs (five RCTs) (Tab II). Eight trials were performed 
in patients with essential hypertension and two trials concerned patients with CHF. Five trials compared ACEIs 
or ARBs vs placebo while four RCTs included a diuretic and/or a beta-blocker as comparator and two trials used 
amlodipine as reference drug (among these RCTS, one study compared an ACEI with either a diuretic or 
amlodipine). 
Brief description of RTCs 
Stop-hypertension-2 
The STOP-Hypertension-2 study was a prospective, randomised trial in 6614 patients aged 70-84 years with 
hypertension (blood pressure > 180 mmHg systolic, > 105 mmHg diastolic, or both) [12]. Patients were 
randomly assigned conventional antihypertensive drugs (beta-blockers as atenolol 50 mg, metoprolol 100 mg, 
pindolol 5 mg daily, or a diuretic combination hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily) or newer 
drugs (ACEIs as enalapril 10 mg or lisinopril 10 mg daily, or calcium channel antagonists as felodipine 2.5 mg 
or isradipine 2-5 mg daily). After 6 years of follow-up, a total of 97 patients (10%) developed T2DM on 
conventional drugs group vs 93 patients (9.6%) in the ACE inhibitors vs 95 patients (9.9%) in the calcium 
antagonists group. The relative risk of developing T2DM on ACEIs averaged 0.96 (95% CI 0.72-1.27), p = 0.77) 
as compared to that observed with conventional drugs. Thus, this trial failed to show any protective effect of 
ACEIs against the development of T2DM. However, the studied population was rather old (mean age: 76 years) 
and the criteria of definition of T2DM were not clearly specified. Moreover, in this trial, drugs from opposing 
study arm were used as second-line agents, raising the possibility of treatment contamination that could 
somewhat dampen the potential protective effect of RAS inhibition. 
CAPPP 
The Captopril Prevention Project (CAPPP) was a prospective, randomised, open trial with blinded evaluation 
[13]. Patients (n = 10985) aged 25-66 years with a measured diastolic blood pressure of 100 mmHg or more on 
two occasions were randomly assigned captopril (50 to 200 mg/day) or conventional antihypertensive treatment 
(diuretics, essentially hydrochlorothiazide and bendrofluazide, and/or beta-blockers, essentially atenolol and 
metoprolol). Follow-up lasted for a mean of 6.1 years. Secondary endpoints included new onset of T2DM. 
Diagnosis of T2DM required at least two abnormal fasting glucose values (> 140 mg/dl or 7.8 mmol/l) or, if not 
unequivocal, confirmation by an oral glucose tolerance test according to the 1985 WHO criteria [14]. The 
incidence of T2DM was lower in the captopril group than in the conventional group (odds ratio or OR: 0.86 
(95% CI, 0.74-0.99); p = 0.039). Similar results were observed in previously untreated patients (n = 5245) after 
adjustment for age, sex, and systolic blood pressure OR: 0.78 (95% CI, 0.62-0.99), p = 0.041. On-treatment 
analysis, rather than intention-to-treat analysis, was also available in the CAPPP trial and the difference was even 
more significant: OR: 0.79 (95% CI, 0.67-0.94); p = 0.007. However, because of the design of the study, it is not 
clear whether the differences in development of T2DM in the CAPPP trial were due to a protective effect of 
ACEI or an adverse effect of beta-blockers or diuretics. Furthermore, the scientific value of this study is 
somewhat dampened by the fact that the randomisation procedure resulted in an imbalance between groups at 
baseline in terms of blood pressure measurements and prevalence of T2DM [15]. Whether this initial imbalance 
might have influenced the results of incidence of new cases of T2DM during the trial is not known. Finally, as in 
the STOP Hypertension-2 trial, drugs from opposing study arm (essentially diuretics) were used as second-line 
agents, again raising the possibility of treatment contamination. 
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Table I: Reduction in the incidence of type 2 diabetes in five large clinical trials investigating the effect of RAS inhibition with ACEIs. TZ: thiazide diuretic; BB: beta-1 blocker. 
NA: not available. AAR: absolute risk reduction. RRR: relative risk reduction. NNT: number needed-to-treat. 
ST0P-Hypertension2 
(12) CAPPP (13) HOPE (16,17) ALLHAT (18) SOLVD (31) 
Clinical trials 
Enalapril/ 
lisinopril TZ/BB captopril TZ/BB ramipril placebo lisinopril chlorthadilone amlodipine enalapril placebo 
Patients            
n total 2205 2213 5492 5493 4645 4652 9054 15255 9048 2111 2117 
age (years) 76.1 76.0 52.4 52.7 66.0 66.0 66.9 66.9 66.9 59.1 59.1 
body mass index 
(kg/m2) 
26.7 26.7 28 28 28.0 28.0 29.8 29.7 29.8 NA NA 
diabetes (%) 10.7 11.4 5.6 4.8* 38.9 38.0 35.5 36.2 36.7 7.3 7.1 
Mean follow-up 
(years) 
6.0 6.0 6.1 6.1 4.5 4.5 4.9 4.9 4.9 3.2 3.2 
Primary 226 221 363 335 651 826 796 1362 798 313 334 
cardiovascular 
outcome n % 




1969 1961 5184 5229 2837 2883 5840 9733 5727 153 138 
New cases of 
diabetes n 
93 97 337 380 102 155 473 1129 561 9 31 
% 9.6 10.0 6.5 7.3* 3.6 5.4** 8.1 11.6** 9.8* 5.9 22.4* 
ARR % -0.4 -0.8 -1.8 -2.5 -1.7 -16.5 
RRR% -4 -14 -34 -30 -17 -78 
NNT 250 125 56 40 59 6 
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Table II: Reduction in the incidence of type 2 diabetes in five clinical trials investigating the effect of RAS inhibition with ARBs. HCT: hydrochlorothiazide. NA: not 



































*p< 0.05. **p<0.001. 
 
 
LIFE (20, 21) SCOPE (22) ALPINE (23) VALUE (24) CHARM (26)  
Clinical trials Losartan Atenolol Candesartan Placebo Candesartan HCT Valsartan Amlodipine Candesartan Placebo 
Patients           
n total 4605 4588 2468 2455 196 196 7649 7596 3796 3793 
age (years) 54.0 54.0 76.4 76.4 54.5 55.4 67.2 67.3 65.9 66.0 
body mass index 
(kg/m2) 
28.0 28.0 27.0 26.9 27.8 28.1 28.6 28.7 28.3 28.2 
diabetes (%) 13.0 13.0 12.5 11.6 0 0 31.1 32.2 28.6 28.3 
Mean follow-up 
(years) 

























4006 3992 2160 2170 196 196 5267 5152 2715 2721 
New cases of 
diabetes 
          
n 241 319 93 115 1 8 690 845 163 202 
% 6.0 8.0** 4.3 5.3 0.5 4.1* 13.1 16.4** 6.0 7.4* 
ARR% -2.0 -1.0 -3.6 -3.3 -1.4 
RRR% -25 -25 -75 -23 -36 
NNT 50 100 28 30 71 
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HOPE 
In the "Heart Outcomes Prevention Evaluation" (HOPE) study, a total of 9297 high-risk patients (55 years of age 
or older) who had evidence of vascular disease or diabetes plus one other cardiovascular risk factor were 
randomly assigned to receive ramipril (10 mg once per day orally) or matching placebo for a mean of 5 years 
[16]. The HOPE study included 5720 patients without known diabetes (2837 on ramipril and 2883 on placebo) 
[17]. The diagnosis of T2DM determined from self-report at follow-up visits every 6 months during a mean 
period of 4.5 years was compared between the 2 groups. One hundred and two individuals (3.6%) in the ramipril 
group developed T2DM compared with 155 (5.4%) in the placebo group (OR: 0.66 (95% CI 0.51-0.85); p < 
0.001). Similar results were noted when different diagnostic criteria were used. The proportion of patients 
diagnosed to have T2DM and a documented glycated haemoglobin of 110% or more above the upper limit of 
normal (1.8% vs 3.0%; OR: 0.60 (95% CI 0.43-0.85); p = 0.003), the proportion of those receiving an oral 
glucose-lowering agent or insulin (2.1% vs 3.6%; OR: 0.56 (95% CI, 0.41-0.77); p < 0.001), and the proportion 
of those with all criteria (1.3% vs 2.5%; OR: 0.51 (95% CI, 0.34-0.76); p < 0.001) were significantly lower in the 
ramipril group compared with the placebo group. These protective effects of ramipril were also consistently seen 
in several subgroups examined. For instance, the relative risk for T2DM in the subgroup individuals who never 
took beta-blockers or diuretics during the study was consistent with the overall results (OR, 0.62; 95% CI, 0.43-
0.90) [17]. Although the data on new diagnoses of T2DM were collected prospectively in the HOPE study, the 
development of T2DM was not a primary or secondary outcome of the trial and this specific outcome was only 
considered in a post-hoc analysis [16, 17]. Therefore, the results, despite their clear statistical significance and 
consistency across subgroups, should be interpreted with caution. 
ALLHAT 
The "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (ALLHAT) was a 
randomised, double-blind, trial designed to determine whether treatment with a calcium channel blocker or an 
ACEI lowers the incidence of coronary heart disease or other cardiovascular disease events vs treatment with a 
diuretic [18]. A total of 33357 participants aged 55 years or older with hypertension and at least one other 
coronary risk factor (36% had type 2 diabetes) were randomly assigned to receive chlorthalidone (12.5 to 25 
mg/day; n = 15255), amlodipine (2.5 to 10 mg/day; n = 9048) or lisinopril (10 to 40 mg; n = 9054). Among 
individuals classified as non diabetic at baseline according to new criteria (initial fasting serum glucose < 126 
mg/dl or 7 mmol/l) [19], the incidence of T2DM was 9.6% in the chlorthalidone group, 7.4% in the amlodipine 
group and 5.8% in the lisinopril group at 2 years (p < 0.001 lisinopril vs chlorthalidone) and 11.6%, 9.8% and 
8.1%, respectively, at 4 years (p < 0.001 lisinopril vs chlorthalidone). Thus, the relative risk reduction (RRR) of 
developing T2DM averaged 30% (95% CI: 23-37%; p < 0.001) among hypertensive patients treated with 
lisinopril as compared to patients treated with the diuretic chlorthalidone and 17% (95% CI: 7-26%; p < 0.01) as 
compared to patients treated with the calcium channel antagonist amlodipine, a molecule that is considered as 
metabolically neutral. 
LIFE 
The LIFE study ("Losartan Intervention For Endpoint reduction in hypertension study") was a double-masked, 
randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood 
pressure 160-200/95-115 mmHg) and left ventricular hypertrophy [20]. Participants were assigned to once daily 
losartan-based (50-100 mg/day) or atenolol-based (50-100 mg/day) antihypertensive treatment for at least 4 
years (mean follow-up of 4.8 years). Among other prespecified endpoints, new onset diabetes, defined according 
to 1985 WHO criteria [14], was assessed by a subcommittee of the steering committee [21]. There was a 25% 
lower incidence of new-onset T2DM in the losartan group than in the atenolol group: 241 cases (6% or 13.0 per 
1000 patient-years of follow-up) vs 319 cases (8% or 17.5 per 1000 patient-years of follow-up); OR: 0.75 (95% 
CI 0.63 to 0.88); p < 0.001). A univariate proportional hazard regression model indicated that random allocation 
to the losartan group resulted in lower incidence of development of T2DM after adjustment for four major risk 
factors, i.e. baseline serum glucose, body mass index, HDL cholesterol and systolic blood pressure levels. After 
correction for these confounding risk factors, the estimated relative risk reduction of T2DM attributable to 
losartan was approximately 29% (p < 0.001) [21]. 
SCOPE 
The Study on Cognition and Prognosis in the Elderly (SCOPE) included 4964 patients aged 70-89 years, with 
systolic blood pressure 160-179 mmHg, and/or diastolic blood pressure 90-99 mmHg [22]. Patients were 
assigned randomly to receive the ARB candesartan (8-16 mg/day) or placebo, with open-label active 
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antihypertensive therapy added as needed, with a mean follow-up of 3.7 years. New-onset T2DM was reported 
in 4.3% and 5.3% of the patients in the candesartan and control groups, respectively, a difference that 
corresponds to a RRR of 25% (p = 0.09). The absence of statistical difference in this study may be explained by 
the shorter follow-up (3.7 years instead of 4.8 to 6.1 years in the other trials). This study was also the only one 
which specifically recruited elderly people (mean age: 76.4 years). Finally, the criteria used to define diabetes 
were not clearly described in the original paper and the development of new diabetes was only considered in a 
post-hoc analysis. 
ALPINE 
The Antihypertensive treatment and Lipid Profile In a North of Sweden Efficacy Evaluation (ALPINE) study 
was a much smaller clinical trial with a lower number of subjects followed during a shorter period of time. 
Furthermore, this RCT was the only one which was not designed to assess cardiovascular prognosis. Rather, it 
compared the metabolic effects of one year treatment with candesartan 16 mg (n = 197, with addition of 
felodipine if needed) and with hydrochlorothiazide 25 mg (n = 196, with addition of atenolol if needed) in 
patients with mild to moderate hypertension (mean age 55 years, 48% of men) [23]. After 12 months, fasting 
plasma glucose increased from 5.29 to 5.42 mmol/l and fasting serum insulin increased from 9.65 to 11.00mIU/L 
in the diuretic group, while slight reductions (respectively, from 5.17 to 5.10 mmol/L and from 9.25 to 8.96 
mlU/L) were observed in the candesartan group (between-group differences: p < 0.001). New T2DM was 
diagnosed in 8 patients in the hydrochlorothiazide group and only one patient in the candesartan group. This 
difference was statistically significant (p = 0.03) despite the rather low number of participants in the study. 
VALUE 
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was an investigator-designed, 
prospective, multinational, double-blind, randomised, active controlled, parallel-group trial [24]. A total of 
15245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events 
were randomised to receive either valsartan 80-160 mg or amlodipine 5-10 mg, possibly combined with 
hydrochlorothiazide. Patients were followed up for a mean of 4.2 years. To detect new-onset diabetes (defined 
according to 1999 WHO criteria) [25] the protocol first excluded all patients who at entry were diagnosed with 
diabetes, received anti-diabetic agents, or had abnormal glucose levels. In the remaining group, individual 
patient study forms and adverse events databases were monitored for new use of antidiabetic drugs and for newly 
reported diabetes. A blood chemistry report was mandatory at the end of the trial, and the diagnosis of new 
T2DM diabetes was made if the serum glucose concentration exceeded 7.8 mmol/l. New-onset diabetes arose in 
significantly fewer hypertensive patients on valsartan than on amlodipine: 690 (13.1%) vs 845 (16.4%), hazard 
ratio: 0.77 (95% CI: 0.69-0.86); p < 0.0001. Absolute relative risk of new T2DM was rather high in this RCT, 
averaging 13.1% in the valsartan group and 16.4% in the amlodipine group. The reduction of new diabetes with 
valsartan seen in VALUE is especially interesting because the comparison group was a calcium antagonist, 
considered to be metabolically neutral. 
CHARM 
The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) study [26] was 
a parallel, double-blind RCT comparing candesartan with placebo in patients with CHF. Overall, 7599 patients 
were randomly assigned candesartan (n = 3803; titrated up to 32 mg once daily) or matching placebo (n = 3796) 
and had a mean follow up of 37.7 months. In patients without a prestudy diagnosis of T2DM, the number of 
patients in the candesartan group who during the programme were newly diagnosed as having T2DM was 
significantly lower than that in the placebo group: candesartan 163 (6%) of 2715 and placebo 202 (7%) of 2721 
(OR = 0.78; 95% CI, 0.64-0.96; p = 0.020). 
The CHARM programme was specifically designed as three parallel, independent, integrated, randomised, 
double-blind, clinical trials comparing candesartan with placebo in three distinct but complementary populations 
of patients with symptomatic CHF: patients with reduced left-ventricular systolic function taking ACEIs 
(CHARM-Added trial) [27], patients with left-ventricular dysfunction intolerant to ACEIs (CHARM-Alternative 
trial) [28] and patients with preserved left-ventricular ejection fraction (CHARM-Preserved trial) [29]. The 
results regarding the effect of candesartan on the incidence of new cases of T2DM was particularly impressive in 
the latter trial, while the differences did not reach statistical significance in the two other sub-trials. Indeed, in the 
CHARM-Preserved trial [28], 40% fewer individuals were diagnosed as having new diabetes in the candesartan 
group than in the placebo group (47 vs 77; OR: 0.60; 95% CI 0.41-0.86; p = 0.005). In the CHARM-Alternative 
trial [27], among patients without a pre-study diagnosis of diabetes, 44 in the candesartan group and 53 in the 
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placebo group developed diabetes (OR: 0.79; 95% CI 0.53-1.18; p = 0.254). In contrast, in the CHARM-Added 
trial [27], no difference was observed between the two populations: 72 (6%) patients in the candesartan group 
and 72 (6%) in the placebo group developed new diabetes (unadjusted OR: 0.98; 95% CI 0.70-1.35; p = 0.88). 
These latter observations suggest that adding an ARB to an ACEI does not provide any further protection against 
T2DM in patients with CHF. 
SOLVD 
In "Studies Of Left Ventricular Dysfunction" (SOLVD), patients with asymptomatic left ventricular dysfunction 
were randomly assigned to receive either placebo (n = 2117) or enalapril (n = 2111) at doses of 2.5 to 20 mg per 
day in a double-blind trial, with a mean follow-up of 37.4 months [30]. There was a trend toward fewer deaths 
due to cardiovascular causes among the patients who received enalapril. A recent retrospective study assessing 
the effect of the ACEI enalapril on the incidence of T2DM in a subgroup of SOLVD reported a dramatic 
reduction of new cases of diabetes in patients with CHF treated with enalapril as compared to those receiving 
placebo [31]. Indeed, 9 among 153 patients (5.9%) developed T2DM after 2.9 years of follow up in the enalapril 
group compared to 31 among 138 (22.4%) in the placebo group (p < 0.0001). By multivariate analysis, enalapril 
remained the most powerful predictor for risk reduction of developing T2DM (hazard ratio = 0.22; 95% CI, 0.10 
to 0.46; p < 0.0001). The effect of enalapril was striking in the subgroup of CHF patients with impaired fasting 
plasma glucose at baseline (1 on enalapril vs 12 patients on placebo developed T2DM; p < 0.0001). 
Meta-analysis of RTCs 
Overall, 2675 new cases of T2DM (7.40%) were observed in the group of 36167 patients receiving a treatment 
with ACEI or ARA as compared with 3842 events (9.63%) in the group of 39902 control patients (Tab I and II). 
All comparisons demonstrated a trend (n = 3) or a significant (n = 8) reduction in the incidence of T2DM after 
RAS inhibition. Results are summarized in figure 1. The overall effect was a mean weighed relative risk 
reduction of T2DM of 22% (95% CI: 18, 26), p < 0.00001. A significant heterogeneity (p =0.004) was observed 
between RCTs with the greatest effect being observed in the two RCTs including lowers numbers of participants 
(ALPINE and SOLVD). The relative risk was similar with ACEIs (OR = 0.77; 95% CI 0.72, 0.82; p = 0.0006) 
and with ARBs (OR = 0.79; 95% CI 0.73, 0.85; p < 0.00001). Furthermore, it was similar in patients with 
arterial hypertension (OR = 0.78; 95% CI 0.75, 0.82; p < 0.0001) and in those with CHF (OR = 0.73; 95% CI 
0.61, 0.89; p = 0.001). Finally, it was present in RCTs comparing RAS inhibition with placebo (OR = 0.73; 95% 
CI 0.64, 0.83; p < 0.00001), with beta-blockers/diuretics (OR = 0.77; 95% CI 0.71, 0.82; p < 0.00001) or with 
the metabolically neutral calcium channel antagonist amlodipine (OR = 0.81; 95% CI 0.75, 0.87; p < 0.00001). 
This excludes the possibility that most of the difference between RAS inhibition and comparator was due to a 
deleterious effect of the comparator (beta-blocker or diuretic), but rather favours the conclusion of a beneficial 
direct effect exerted by ACEI or ARBs. The absolute risk of developing T2DM over a mean follow-up period of 
4 years averaged 7.40% in the group treated with ACEI or ARB and 9.63% in the group receiving placebo or a 
reference drug, corresponding to a mean absolute risk reduction of 2.23% (p < 0.00001). Thus, the number-
needed-to-treat to avoid one new case of T2DM averaged 45 patients over a period of 4-5 years. 
DISCUSSION 
T2DM prevention is considered as a main objective according to the WHO [29] and the American Diabetes 
Association [30]. Lifestyle changes play a major role and have proven a remarkable efficacy, although various 
pharmacological interventions also showed a significant prevention effect [32-34]. Insulin resistance plays a 
major role in the pathophysiology of T2DM [35-37]. Such metabolic abnormality is also present in most patients 
with arterial hypertension [38, 39] or CHF [40, 41]. Interestingly, as essential hypertension [4], CHF has been 
shown to be associated with a higher risk of developing T2DM [42], in a proportional manner to the functional 
class of the patients [43]. Considering the high prevalence of hypertension in the general population, especially 
in presence of overweight (abdominal adiposity) or obesity, it would be of major importance from a public 
health point of view to evaluate the potential influence of RAS inhibition on the incidence of T2DM in 
individuals with essential hypertension. The present meta-analysis demonstrates that RAS inhibition results in a 
consistent and significant 22% RRR of T2DM incidence. Such protective effect is only slightly lower than that 
observed with antidiabetic agents such as metformin (RRR = -31% without drug withdrawal and RRR = -25% 
after 1-2 weeks of washout in the Diabetes Prevention Program) [44, 45] or acarbose (RRR = -25% without drug 
withdrawal and RRR = -14% after a 3-month wash-out period in the STOP-NIDDM trial) [46]. As previously 
questioned, it is not clear whether the protective effects of oral antidiabetic agents are preventing, delaying or 
simply masking effects [47]. The amplitude of the protection effect resulting from RAS inhibition was similar 
with ACEI (RRR = -23%) and ARB (RRR = -21%), despite previous observations  from glucose clamp  studies  
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suggesting  that ACEIs might exert a greater effect on insulin-mediated glucose disposal than ARBs [48]. The 
number needed-to-treat (around 45 subjects over a 4-5 year period) to avoid one new case of T2DM may appear 
rather high as compared to other trials. However, it should be kept in mind that the main purpose of RAS 
inhibition was not to prevent T2DM, but rather to provide a cardiovascular protection [9]. Therefore, the 
prevention of T2DM should be considered as an additional beneficial effect and the number needed-to-treat 
should be considered in view of the high number of individuals with hypertension (or CHF) in the general 
population, a proportion that may further increase in the next decades in a population with increasing prevalence 
of obese and elderly subjects. Finally, as discussed recently [6], nearly all randomised controlled trials reported 
intention-to-treat rather than on-treatment analyses when calculating diabetes risk. On-treatment analysis may be 
the more accurate method if large differences in treatment adherence between study arms were observed. For 
instance, in the HOPE trial, 90% of patients randomised to ramipril remained on the study drug and 27% of 
placebo-treated patients were taking open-label ACEIs [17]. Therefore, the difference in risk of T2DM between 
the two treatments is underestimated using the intention-to-treat analysis as published rather than the on-
treatment analysis (data not provided). The CAPPP trial reported both types of analysis and indeed found a 
greater difference between drug classes with the on-treatment analysis rather than with the intention-to-treat 
analysis [13]. However, as already mentioned, treatment contamination limits the conclusion that can be drawn 
from this trial. Ideally, RCTs should report both types of analyses, particularly when large discrepancies in 
treatment adherence between study arms are observed [6]. 
The positive effect after RAS inhibition could not be simply interpreted as a worse effect in the comparative 
group as it was observed not only vs beta-blocker or diuretic [RRR = -23%), but also vs placebo [RRR = -27%) 
or vs amlodipine, a calcium channel antagonist that is generally considered as metabolically neutral [RRR = -
19%). However, one may argue that most patients in the placebo groups also received other antihypertensive 
agents that might negatively influence the metabolic profile of the patients. If this was probably true, this was the 
case in the two parallel groups as all trials were conducted in a double-bind manner, and thus RAS inhibition 
provided a significant protection against the development of T2DM in all such circumstances. The criteria used 
to define T2DM were not always clearly specified and varied from trial to trial. However, in the HOPE trial, the 
reduction of the incidence of new cases of T2DM was significant whatever the criteria used to define diabetes 
[17] and there was a between-trial consistent favourable effect whatever the definition of T2DM. Finally, the 
major criticism against published studies assessing the effect of RAS inhibition on the incidence of T2DM was 
that the results were the product of a post hoc analysis or the secondary results of trials projected for a different 
scope as the primary endpoint was indeed cardiovascular protection. Thus, the positive findings of the present 
meta-analysis should receive further and definite confirmation from RCTs in which the incidence of new T2DM 
will be considered as primary or pre-specified secondary endpoints and the criteria used to define diabetes will 
be widely accepted. Three large-scale trials specifically designed to answer this important question are ongoing 
in both hypertensive and non-hypertensive individuals: DREAM ("Diabetes REduction Approaches with 
ramipril and rosiglitazone Medications"), NAVIGATOR ("Nateglinide And Valsartan in Impaired Glucose 
Tolerance Outcomes Research") and ONTARGET ("Telmisar-tan Alone and in combination with Ramipril 
Global Endpoint trial")—TRANSCEND ("Telmisartan Randomized Assessment Study in Angiotensin Inhibitor-
Intolerant Patients with Cardiovascular Disease"). A concise description of these three ongoing RCTs has been 










Published in:  Diabètes & Métabolism (2004), vol. 30, iss. 6, pp. 487-496 
Status : Postprint (Author’s version) 
Figure 1: Meta-analysis of randomised clinical trials evaluating the effect of RAS inhibition using either an 
ACEI or an ARB ["treatment") on the relative risk of development of new diabetes in hypertensive patients, as 
compared to either a reference drug or a placebo ["control"), n = cases of new diabetes. N: total number of non-
diabetic patients at entry. 
 
 
As previously discussed [9], the mechanisms that may explain the preventive effect of RAS inhibition on the 
development of T2DM are complex. From a theoretical point of view, preventing T2DM by RAS inhibition may 
result from a preservation of beta-cell function and/or an enhancement of insulin sensitivity, thereby decreasing 
the need for pancreatic insulin secretion [35-37]. Targeting RAS may lead to alterations in microcirculation and 
changes in ionic status that indeed could potentially affect both islet insulin secretion and cellular insulin action. 
However, unexpected mechanisms might also play a role as newly recognised components of the RAS seem to 
modulate cardiovascular and renal regulation [7] or even adipocyte turnover [49]. Intimate relationships have 
been described between adipose tissue and RAS [50, 51] and the strong association between obesity and T2DM 
is well known [52]. Besides a pure haemodynamic effect [53], a direct effect on cellular insulin action by 
blocking ATII has also been described [54-56]. Finally, a possible agonist effect on PPAR-gamma has been 
recently described with some ARBs whith high lipophilicity such as telmisartan [57, 58]. The underlying 
mechanisms possibly involved in the reduction of new onset diabetes with RAS inhibition will be more 
extensively described in a next paper [59]. 
CONCLUSION 
Besides life-style modifications and classical pharmacological strategies using various antidiabetic or anti-
obesity agents, drugs that inhibit RAS activity may be considered as a valuable approach to prevent T2DM. 
Strategies that interrupt RAS offer effective antihypertensive treatment as well as nephroprotection, especially in 
diabetic patients. In addition, they have demonstrated their efficacy in reducing cardiovascular disease mortality 
and morbidity in high-risk individuals such as those with arterial hypertension and/or diabetes mellitus. Finally, 
they may improve carbohydrate tolerance in some patients, and are essentially neutral (or even slightly positive 
in certain conditions) on insulin sensitivity. The recent consistent observations in individuals with arterial 
hypertension or CHF of a protective effect on the development of T2DM with ACEIs or ARBs are enticing and 
emphasise that there are many aspects of the pathogenesis and treatment of T2DM that still need to be 
uncovered. Ongoing large RCTs specifically designed to investigate the effect of RAS inhibition on the 
incidence of T2DM should confirm the present observations and provide more extensive metabolic data that will 
help to better understand the potential mechanisms underlying the protective effect against T2DM. In case of 
positive results, patients at very high risk to develop T2DM, such as obese patients with impaired glucose 
tolerance independently of the presence of arterial hypertension, would be an interesting new target population to 
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